Will Kidney Disease Patients Finally Receive New Drug Class?
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?
Medscape Medical News
source https://www.medscape.com/viewarticle/997528?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/997528?src=rss
Comments
Post a Comment